NO990351L - FremgangsmÕte for fremstilling av den venstredreiende og h°yredreiende enantiomer av et 1-[(4-klorfenyl)fenylmetyl]-piperazin - Google Patents

FremgangsmÕte for fremstilling av den venstredreiende og h°yredreiende enantiomer av et 1-[(4-klorfenyl)fenylmetyl]-piperazin

Info

Publication number
NO990351L
NO990351L NO990351A NO990351A NO990351L NO 990351 L NO990351 L NO 990351L NO 990351 A NO990351 A NO 990351A NO 990351 A NO990351 A NO 990351A NO 990351 L NO990351 L NO 990351L
Authority
NO
Norway
Prior art keywords
turn
chlorophenyl
ethyl
phenylmethyl
piperazine
Prior art date
Application number
NO990351A
Other languages
English (en)
Other versions
NO306616B1 (no
NO990351D0 (no
Inventor
Eric Cossement
Guy Bodson
Jean Gobert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO990351D0 publication Critical patent/NO990351D0/no
Publication of NO990351L publication Critical patent/NO990351L/no
Publication of NO306616B1 publication Critical patent/NO306616B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
NO990351A 1993-03-15 1999-01-26 Fremgangsmåte for fremstilling av den venstredreiende og höyredreiende enantiomer av et 1-[(4-klorfenyl)fenylmetyl]-piperazin NO306616B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305282A GB9305282D0 (en) 1993-03-15 1993-03-15 Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Publications (3)

Publication Number Publication Date
NO990351D0 NO990351D0 (no) 1999-01-26
NO990351L true NO990351L (no) 1999-01-26
NO306616B1 NO306616B1 (no) 1999-11-29

Family

ID=10732080

Family Applications (2)

Application Number Title Priority Date Filing Date
NO940881A NO305908B1 (no) 1993-03-15 1994-03-11 Enantiomerer av 1-[(4-klorfenyl)fenylmethyl]-4-[(4-methylfenyl)sulfonyl]piperazin og fremgangsmåte for fremstilling av disse
NO990351A NO306616B1 (no) 1993-03-15 1999-01-26 Fremgangsmåte for fremstilling av den venstredreiende og höyredreiende enantiomer av et 1-[(4-klorfenyl)fenylmetyl]-piperazin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO940881A NO305908B1 (no) 1993-03-15 1994-03-11 Enantiomerer av 1-[(4-klorfenyl)fenylmethyl]-4-[(4-methylfenyl)sulfonyl]piperazin og fremgangsmåte for fremstilling av disse

Country Status (23)

Country Link
US (17) US5478941A (no)
EP (3) EP0955295B1 (no)
JP (3) JP3267434B2 (no)
KR (1) KR100322415B1 (no)
AT (2) ATE267185T1 (no)
AU (1) AU678426B2 (no)
CA (2) CA2118859C (no)
DE (2) DE69424893T2 (no)
DK (1) DK0617028T3 (no)
ES (2) ES2147569T3 (no)
FI (3) FI105477B (no)
GB (1) GB9305282D0 (no)
GR (1) GR3034340T3 (no)
HU (1) HU219230B (no)
NO (2) NO305908B1 (no)
NZ (1) NZ260062A (no)
PL (1) PL178546B1 (no)
PT (1) PT617028E (no)
RU (1) RU2118320C1 (no)
SG (1) SG43683A1 (no)
SI (2) SI0617028T1 (no)
TW (1) TW237452B (no)
ZA (1) ZA941724B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
JPH08501561A (ja) * 1992-09-24 1996-02-20 セプラコア,インコーポレイテッド (−)セチリジンを用いたアレルギー疾患の治療のための組成物
ES2128556T3 (es) * 1992-09-24 1999-05-16 Sepracor Inc Tratamiento transdermico de la urticaria usando (+)-cetirizina opticamente pura.
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
EP0690051B1 (en) * 1994-01-14 2001-07-18 Azwell Inc. Diazacycloalkanealkylsulfonamide derivative
CN1058638C (zh) * 1995-06-27 2000-11-22 中国药品生物制品检定所 胞内分枝杆菌变态反应原提取方法
WO1998055459A1 (en) 1997-06-04 1998-12-10 Azwell Inc. Process for producing piperazinesulfonamide derivatives and salts thereof
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
IL124195A (en) * 1998-04-23 2000-08-31 Chemagis Ltd Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid
US6432961B1 (en) * 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
PE20001566A1 (es) * 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
SK285641B6 (sk) * 1999-11-30 2007-05-03 Egis Gy�Gyszergy�R Rt. Spôsob prípravy {2-[4-(alfa-fenyl-p-chlórbenzyl)piperazin-1- yl]etoxy}octovej kyseliny a nové medziprodukty
JP2002249487A (ja) 2001-02-22 2002-09-06 Sumitomo Chem Co Ltd 4−(tert−ブトキシカルボニル)ピペラジン誘導体、その光学活性な酸付加塩、それらの製造法、およびそれらを用いる光学活性な1−[(置換フェニル)フェニルメチル]ピペラジンの製造法。
US6977301B1 (en) 2001-05-29 2005-12-20 Ucb, S.A. Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
US7199241B1 (en) 2001-05-29 2007-04-03 Ucb, S.A. Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
AR039156A1 (es) * 2002-03-28 2005-02-09 Novartis Ag Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide
CA2488114A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy`S Laboratories, Inc. Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
US7577727B2 (en) * 2003-06-27 2009-08-18 Newisys, Inc. Dynamic multiple cluster system reconfiguration
KR100503443B1 (ko) 2004-02-02 2005-07-22 한림제약(주) 광학적으로 활성인 세티리진 또는 그의 염의 제조방법
ES2326689T3 (es) * 2005-03-03 2009-10-16 Ucb Farchim, S.A. Sales de piroglutamato y su uso en la resolucion optica de intermedios para la sintesis de dextrocetirizana y levocetirizana.
HU227074B1 (en) * 2005-12-08 2010-06-28 Egis Gyogyszergyar Nyrt An optically active carbamic acid derivative, method for producing the same and use as a pharmaceutical intermediate
EA016523B1 (ru) * 2007-03-12 2012-05-30 Крка, Товарна Здравил, Д.Д., Ново Место Способ получения левоцетиризина и его промежуточных соединений
EP2167479B1 (en) 2007-06-15 2013-09-11 Symed Labs Limited Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates
US20090062305A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched cetirizine
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
KR101427100B1 (ko) 2007-10-23 2014-08-08 주식회사 씨트리 광학활성을 갖는 1-[(4-클로로페닐)페닐메틸]-피페라진의제조방법
US7989623B2 (en) * 2007-11-21 2011-08-02 Synthon Bv Process for making n-(diphenylmethyl)piperazines
DE602007012725D1 (de) 2007-11-21 2011-04-07 Synthon Bv Verfahren zur Herstellung von N-(Diphenylmethyl)piperazinen
KR100954755B1 (ko) * 2007-12-17 2010-04-27 한미약품 주식회사 (r)-(-)-1-[(4-클로로페닐)페닐메틸]피페라진의 제조방법
AU2009254959B2 (en) * 2008-06-02 2014-01-30 Cipla Limited Processes for the synthesis of levocetirizine and intermediates for use therein
KR100998067B1 (ko) 2008-09-08 2010-12-03 주식회사 삼오제약 비스(1-[(4-클로로페닐)페닐메틸]피페라진)-2,3-디벤조일 타르타르산 신규 중간체 염 및 이를 이용한 광학 활성적으로 순수한 1-[(4-클로로페닐)페닐메틸]피페라진을 분리하는 분리방법
US20100145049A1 (en) * 2008-11-21 2010-06-10 Jie Zhu Process for making n-(diphenylmethyl)piperazines
AR076363A1 (es) * 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida
CN101928223A (zh) * 2009-06-26 2010-12-29 华东理工大学 一种(r)-(-)-4-氯二苯甲胺的拆分方法
WO2012101475A1 (en) 2011-01-27 2012-08-02 Jubilant Life Sciences Limited An improved process for the preparation of antihistaminic drugs via a novel carbamate intermediate
KR101418404B1 (ko) 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
WO2013158318A1 (en) 2012-04-16 2013-10-24 Zemtsov Enterprises, Llc Formulations and methods for treatment of acne and inflammatory skin conditions
CN103613567A (zh) * 2012-11-09 2014-03-05 焦作福瑞堂制药有限公司 盐酸氯环利嗪的合成工艺
KR102226833B1 (ko) 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CN104045607B (zh) * 2014-05-21 2016-04-13 丽珠医药集团股份有限公司 一种盐酸西替利嗪的纯化方法
CN111205247B (zh) * 2020-04-22 2020-08-14 湖南九典宏阳制药有限公司 左旋西替利嗪的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2709169A (en) * 1955-05-24 X c chs
CA568380A (en) * 1959-01-06 Morren Henri Ethers of piperazine and method of their preparation
US2899436A (en) * 1959-08-11 chjch
BE540057A (no) *
BE523901A (no) *
GB752331A (en) * 1948-09-30 1956-07-11 Abbott Lab Improvements in or relating to n, n-disubstituted piperazines and process of preparing the same
US2861072A (en) * 1952-07-19 1958-11-18 Abbott Lab Preparation of piperazine derivatives
US2709167A (en) * 1952-09-10 1955-05-24 Geigy Ag J R Chromium-containing monoazo dyestuffs
US2897436A (en) * 1954-09-29 1959-07-28 Amchem Prod Indicating and control apparatus for electrolyte concentration and the like
US3406174A (en) * 1964-10-23 1968-10-15 Sandoz Ag Benzylsulfamides
FI75816C (fi) * 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
DE3640247A1 (de) * 1986-11-25 1988-05-26 Basf Ag Fungizide cyclohexylamine
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JP2559463B2 (ja) * 1988-06-01 1996-12-04 ダイセル化学工業株式会社 不斉中心に2個の芳香族基を有する化合物の光学分割方法
JPH0239947A (ja) * 1988-07-29 1990-02-08 Seikosha Co Ltd 印字ヘッド
GB8827391D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
US4882432A (en) * 1989-01-09 1989-11-21 American Home Products Corporation Polycyclic-carbamic acid piperazinoalkyl esters and amides
US5087627A (en) * 1989-03-15 1992-02-11 Santen Pharmaceutical Co., Ltd. Agent for treatment of disorders of the cerebro-neural transmission system
SG43860A1 (en) * 1990-09-10 1997-11-14 Mitsubishi Electric Corp Coding apparatus
JPH08501561A (ja) * 1992-09-24 1996-02-20 セプラコア,インコーポレイテッド (−)セチリジンを用いたアレルギー疾患の治療のための組成物
ES2128556T3 (es) 1992-09-24 1999-05-16 Sepracor Inc Tratamiento transdermico de la urticaria usando (+)-cetirizina opticamente pura.
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Also Published As

Publication number Publication date
ES2147569T3 (es) 2000-09-16
US20060229319A1 (en) 2006-10-12
HU9400727D0 (en) 1994-06-28
NO306616B1 (no) 1999-11-29
HK1024232A1 (en) 2000-10-05
JP2006342190A (ja) 2006-12-21
FI941134A0 (fi) 1994-03-10
FI105914B (fi) 2000-10-31
NO305908B1 (no) 1999-08-16
GR3034340T3 (en) 2000-12-29
CA2118859A1 (en) 1994-09-16
HU219230B (en) 2001-03-28
SI0617028T1 (en) 2000-10-31
US20040122023A1 (en) 2004-06-24
US20070142400A1 (en) 2007-06-21
ATE193889T1 (de) 2000-06-15
US20050176732A1 (en) 2005-08-11
US20060229320A1 (en) 2006-10-12
FI941134L (fi) 1994-09-16
RU2118320C1 (ru) 1998-08-27
US20050182069A1 (en) 2005-08-18
GB9305282D0 (en) 1993-05-05
PT617028E (pt) 2000-11-30
NO990351D0 (no) 1999-01-26
TW237452B (no) 1995-01-01
EP1413307A1 (fr) 2004-04-28
US20040122021A1 (en) 2004-06-24
HUT70959A (en) 1995-11-28
JP3880842B2 (ja) 2007-02-14
US5792770A (en) 1998-08-11
SG43683A1 (en) 1997-11-14
DE69433802T2 (de) 2005-05-12
JP3267434B2 (ja) 2002-03-18
JP2002201187A (ja) 2002-07-16
US20060252934A1 (en) 2006-11-09
NZ260062A (en) 1995-09-26
KR100322415B1 (ko) 2002-06-20
AU678426B2 (en) 1997-05-29
US20040072845A1 (en) 2004-04-15
PL178546B1 (pl) 2000-05-31
EP0617028B1 (fr) 2000-06-14
NO940881L (no) 1994-09-16
US5478941A (en) 1995-12-26
US6436942B1 (en) 2002-08-20
AU5777194A (en) 1994-09-22
FI19991730L (fi) 1999-08-16
EP0955295B1 (fr) 2004-05-19
US5703082A (en) 1997-12-30
US20030105113A1 (en) 2003-06-05
SI0955295T1 (en) 2004-10-31
US20030204089A1 (en) 2003-10-30
ATE267185T1 (de) 2004-06-15
EP0617028A1 (fr) 1994-09-28
FI105915B (fi) 2000-10-31
US20050182070A1 (en) 2005-08-18
US20030105112A1 (en) 2003-06-05
CA2443216A1 (en) 1994-09-16
FI105477B (fi) 2000-08-31
DE69424893T2 (de) 2000-10-12
ES2221262T3 (es) 2004-12-16
CA2443216C (en) 2007-05-08
EP0955295A1 (fr) 1999-11-10
FI19991729L (fi) 1999-08-16
DE69433802D1 (de) 2004-06-24
ZA941724B (en) 1994-10-13
DE69424893D1 (de) 2000-07-20
NO940881D0 (no) 1994-03-11
CA2118859C (en) 2004-07-13
JPH072816A (ja) 1995-01-06
DK0617028T3 (da) 2000-09-04

Similar Documents

Publication Publication Date Title
NO990351D0 (no) FremgangsmÕte for fremstilling av den venstredreiende og h°yredreiende enantiomer av et 1-[(4-klorfenyl)fenylmetyl]-piperazin
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
NO306994B1 (no) Heteroarylpiperidiner, pyrrolidiner og piperaziner, deres anvendelse for fremstilling av antipsykotika og analgetika samt farmasoeytiske preparater inneholdende forbindelsene
YU43794A (sh) Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje
YU44895A (sh) Višejedinični dozni oblici u tabletama koji sadrže omeprazol i jednu njegovu alkalnu so ili jedan enantiomer omeprazola ili jednu njegovu alkalnu so
MY153718A (en) Formulation of human antibodies for treating tnf-(?) associated disorders
NO20023037D0 (no) Nye piperidin- og piperazinderivater
FI913142A0 (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
UA74337C2 (uk) Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії
ATE152448T1 (de) Heterozyklische alkylamide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
DK591488D0 (da) 1-acyl-3-oe4-(2-pyrimidinyl)-1-piperazinylaapropan-forbindelser, deres anvendelse til fremstilling af et angstdaempende laegemiddel og farmaceutiske praeparater indeholdende disse forbindelser
NZ334571A (en) Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus
YU67402A (sh) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
DE3875543D1 (de) 1-(2-(phenylmethyl)phenyl)-piperazin-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
HUP0302842A2 (hu) Az 1-[6-klór-5-(trifluor-metil)-2-piridinil]-piperazin-hidroklorid kristályalakjai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO881554L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-((1,1-difenyl)-1-alkenyl)piperazin-derivater og farmasoeytisk aksepterbare salter av disse derivater.
EE05178B1 (et) 1,3-dioksolaanid, nende saamine ja kasutamine k”havastaste ravimite valmistamiseks ning neid sisaldavad farmatseutilised kompositsioonid
ATE17120T1 (de) N-((2-oxo-1-pyrrolidinyl)acetyl)piperazine, verfahren zu ihrer herstellung sowie ihre salze und ihre verwendung in pharmazeutischen zubereitungen.
ATE306276T1 (de) Verwendung von selenithältigen wässerigen lösungen zur herstellung eines medikaments zur behandlung viraler erkrankungen und pigmentflecken

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees